Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
NGL Fine-Chem Limited is an integrated manufacturer of pharmaceutical APIs, primarily focused on veterinary APIs, plus human APIs, intermediates and a small finished-dosage portfolio, operating three state-of-the-art facilities in Tarapur and Navi Mumbai with WHO-GMP and other international accreditations and a large global customer base.
Q3FY26 financials show accelerating recovery with revenue from operations at ₹127.51 crore (up 43% YoY) and 9MFY26 revenue at ₹351.89 crore (up 28.7% YoY); EBITDA improved sharply to ₹22.31 crore in Q3 with a 17.5% margin, reflecting easing raw material costs and operational efficiencies that materially lifted profitability.
The company is reducing product concentration and expanding geographic reach: top-3 product share declined to 28% and top-10 products to 65% in Q3FY26, while regulatory filings (CEPs, ASMF approvals, VMF filings) indicate deliberate progress toward higher-value regulated markets and an ambition to increase revenue from controlled markets.
Operational differentiation includes ~95% in-house manufacturing, 75% production from zero-liquid-discharge facilities and strong backward integration, which together support cost competitiveness, consistent quality with no market rejection in 15 years, and the company’s stated goal of achieving asset turnover greater than two times from new investments.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,761 Cr
High Risk
30.8
37.9
1.1
5.1
3,595.00
1,261.00
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
NGL Fine Chem Ltd (NGLFINE) is currently trading at 2,850.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
NGL Fine-Chem Limited is an integrated manufacturer of pharmaceutical APIs, primarily focused on veterinary APIs, plus human APIs, intermediates and a small finished-dosage portfolio, operating three state-of-the-art facilities in Tarapur and Navi Mumbai with WHO-GMP and other international accreditations and a large global customer base. Q3FY26 financials show accelerating recovery with revenue from operations at ₹127.51 crore (up 43% YoY) and 9MFY26 revenue at ₹351.89 crore (up 28.7% YoY); EBITDA improved sharply to ₹22.31 crore in Q3 with a 17.5% margin, reflecting easing raw material costs and operational efficiencies that materially lifted profitability. The company is reducing product concentration and expanding geographic reach: top-3 product share declined to 28% and top-10 products to 65% in Q3FY26, while regulatory filings (CEPs, ASMF approvals, VMF filings) indicate deliberate progress toward higher-value regulated markets and an ambition to increase revenue from controlled markets. Operational differentiation includes ~95% in-house manufacturing, 75% production from zero-liquid-discharge facilities and strong backward integration, which together support cost competitiveness, consistent quality with no market rejection in 15 years, and the company’s stated goal of achieving asset turnover greater than two times from new investments.
Over the past 52 weeks, NGL Fine Chem Ltd has traded between a low of ₹1,261.00 and a high of ₹3,595.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
NGL Fine Chem Ltd has a market capitalization of approximately 1,687.45. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
NGL Fine Chem Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.50 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,687.45 Cr, NGL Fine Chem Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
NGL Fine Chem Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of NGL Fine Chem Ltd is 29.50. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board meeting is scheduled for Wednesday, August 12, 2026, to consider and approve results for the quarter ended June 30, 2026.
Discovery themes featuring this stock
Bearish
1
Neutral
6
Bullish
7
Bearish
13
Neutral
6
Bullish
27
Bearish
12
Neutral
0
Bullish
20
Bearish
1
Neutral
6
Bullish
7
Bearish
1
Neutral
6
Bullish
7
Bearish
12
Neutral
0
Bullish
20
Bearish
12
Neutral
0
Bullish
20
Bearish
12
Neutral
0
Bullish
20
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
19.75 | 1,861 Cr | 21.76 | 4.48 | 0.51 | 18.42 | 24.46 | 16.02 | ||
2190.00 | 1,860 Cr | 13.58 | 5.16 | 0.50 | 15.45 | 14.34 | 20.20 | ||
2729.00 | 1,687 Cr | 29.50 | 5.13 | 0.06 | 14.62 | 15.37 | 10.49 | ||
683.55 | 1,640 Cr | 37.39 | 5.95 | 0.15 | 15.92 | 21.28 | 13.63 | ||
227.55 | 1,498 Cr | 32.94 | 5.46 | 1.79 | 15.60 | 20.59 | 14.36 | ||
496.05 | 1,432 Cr | 26.54 | 3.87 | 0.99 | 17.42 | 23.31 | 10.61 | ||
26.40 | 1,403 Cr | 50.02 | 6.09 | 0.00 | 12.38 | 16.89 | 9.04 | ||
| Median: 7 Co. | — | 496.05 | 1,640 Cr | 29.50 | 5.16 | 0.50 | 15.60 | 20.59 | 13.63 |
